What is Centile Bio?
Centile Bio is an early-stage company leveraging artificial intelligence in the neuroimaging sector. The company is developing a diagnostic platform designed to transform standard brain scans, such as MRI and CT, into quantitative, population-referenced biomarkers. By constructing extensive reference models of brain structure and function, Centile Bio aims to empower clinicians and researchers with advanced tools for detecting abnormalities associated with developmental, aging, and neurological conditions.
How much funding has Centile Bio raised?
Centile Bio has raised a total of $3.1M across 1 funding round:
Private Equity
$3.1M
Private Equity (2026): $3.1M, investors not publicly disclosed
What's next for Centile Bio?
The recent major strategic investment positions Centile Bio for significant scaling and further development of its AI-driven neuroimaging platform. This enterprise-level funding suggests a transition from early-stage research to broader clinical validation and market penetration. The company is likely to focus on expanding its data sets, refining its biomarker algorithms, and forging strategic partnerships within the healthcare and research communities to accelerate the adoption of its diagnostic technology.
See full Centile Bio company page
